Author:
von Minckwitz G.,Rezai M.,Fasching P.A.,Huober J.,Tesch H.,Bauerfeind I.,Hilfrich J.,Eidtmann H.,Gerber B.,Hanusch C.,Blohmer J.U.,Costa S.D.,Jackisch C.,Paepke S.,Schneeweiss A.,Kümmel S.,Denkert C.,Mehta K.,Loibl S.,Untch M.
Reference13 articles.
1. Definition and impact of pathological complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes;von Minckwitz;J Clin Oncol,2012
2. Meta-analysis results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC);Cortazar;San Antonio Breast Cancer Conference San Antonio Texas,2012
3. First efficacy results of a randomized, open-label, phase II study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer;O'Shaughnessy;Cancer Res,2010
4. Gvon Minckwitz JU Blohmer SD Costa. Response-Guided neoadjuvant chemotherapy for breast cancer. J Clin Oncoldoi:10.1200/JCO.2012.45.0940
5. Capecitabine in addition to anthracycline/taxane-based neoadjuvant treatment in patients with primary breast cancer: The Phase III GeparQuattro Study;von Minckwitz;J Clin Oncol,2010
Cited by
59 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献